Rationale for the use of platelet aggregation inhibitors in PAD patients

Vascular Medicine

Volumn 6, Issue 3 SUPPL., 2001, Pages 13-15

  Agnelli, G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Atherothrombosis; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; LOTRAFIBAN; ORBOFIBAN; PLACEBO; SIBRAFIBAN; TICLOPIDINE; XEMILOFIBAN;

ALLERGY; ANEMIA; ARTERY DISEASE; ARTERY THROMBOSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DISEASE MARKER; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; ISCHEMIA; MEDICAL EDUCATION; META ANALYSIS; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RASH; RISK FACTOR; RISK MANAGEMENT; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBUS; TREATMENT FAILURE; UNSTABLE ANGINA PECTORIS; ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; APLASTIC ANEMIA; ARTICLE; BLOOD CLOTTING; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; DISEASE COURSE; HEART DEATH; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPULATION DISTRIBUTION; RISK REDUCTION; THROMBOSIS;

EID: 0035207382     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x0100600i104     Document Type: Conference Paper

References (35)

1. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing
2. Atherosclerosis: A unifying disorder with diverse manifestations
3. Basis data related to the natural history of intermittent claudication
4. Antithrombotic drugs in peripheral obliterative arterial diseases
5. The role of platelets in ischemic stroke
6. Comparative safety and tolerability of clopidogrel and aspirin: Results from CAPRIE
7. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥ 62 years of age
8. Pre-existing cardiovascular conditions and long-term prognosis after initial myocardial infarction: The Framingham Study
9. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories
10. Treating atherosclerotic disease: Current strategies
11. Peripheral arterial disease - Epidemiological aspects
12. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
13. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
14. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients
15. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
16. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
17. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
18. European Stroke Prevention Study 2. Efficacy and safety data
19. Fatal neutropenia and thrombocytopenia associated with ticlopidine
20. Antiplatelet drugs. A comparative review
21. The Persantine-aspirin reinfarction study
22. Persantine Aspirin Trial in cerebral ischemia
23. A long-term randomized trial of anti-aggregating drugs in threatened stroke
24. 'AICLA' controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia
25. Platelet-active drugs. The relationships among dose, effectiveness and side effects
26. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates
27. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit
28. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
29. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes with ST-segment elevation
30. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. Evaluation of oral xemilofiban in controlling thrombotic events
31. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
32. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
33. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes
34. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial
35. SmithKline Beecham terminates clinical trial of lotrafiban